with the Mann-Whitney U or Kruskal-Wallis H. Logistic regression set prophylactic levetiracetam as the dependent variable using forward selection. The analysis was repeated in patients who survived at least 5 days after ICH. 10 
Results

Multicenter Cohort
The multicenter cohort composed 3422 patients, of whom 1777 (51.9%) were men with a mean age of 57.7±15.9 years. Race/ethnicity and levetiracetam were associated (Table 1) . Whites were almost twice as likely as blacks to be administered levetiracetam (odds ratio: 1.71; 95% confidence interval, 1.43-2.05; P<0.0001). Age and sex were not associated with levetiracetam administration.
Single-Center Cohort
Among 450 patients with spontaneous ICH ( Data are represented as n (%). Data do not sum to 3422 because of missing data in some patients on race/ethnicity. Data are represented as n(%), median (Q1-Q3), or mean±SD. Lobar hematoma, depressed GCS, older age, and known alcohol abuse were associated with levetiracetam administration. In multivariate analysis, only lobar hematoma was associated with levetiracetam administration. GCS indicates Glasgow Coma Scale; and ICH, intracerebral hemorrhage.
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and Hispanics (n=19, 6%) were less likely to have a history of hypertension (P=0.00007).
Factors associated with levetiracetam administration are shown in Table 2 . Whites were nearly twice as likely as blacks to be administered levetiracetam (odds ratio: 1.9; 95% confidence interval, 1.25-2.89; P=0.002). In multivariate analysis, hematoma location entered first and rendered other variables nonsignificant. Similar results were found for patients who survived at least 5 days and patients with seizures.
Discussion
Whites were approximately twice as likely as blacks to receive levetiracetam. This apparent disparity was confounded by hematoma location, with whites more likely to have lobar hematomas, the clinical factor most closely linked to a higher risk of seizures.
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Although prophylactic seizure medications are no longer recommended after ICH, 2,3 their use remains common. 6 The use of levetiracetam in patients with a lobar hematoma is rational, if not strictly compliant with the guidelines, one of many scenarios where clinical practice deviates from evidence-based recommendations. 12 Disparities in prophylactic phenytoin were not examined because we discontinued its use in 2009.
Associations between seizure medications and outcomes were not evaluated. Adverse events associated with phenytoin are relatively easy to detect. 4 Levetiracetam has fewer side effects than phenytoin, and any adverse effects on cognition or behavior are likely to be detected only in patients already considered to have a good outcome. 13 Other validated scores of health-related quality of life and cognition could be a useful adjunct. 14, 15 In sum, we found that an apparent disparity in the use of seizure medications was confounded by hematoma location. There are likely to be other disparities found in the care of patients with ICH, some of which are confounded.
